576 related articles for article (PubMed ID: 18627375)
21. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis.
Gordon K; Korman N; Frankel E; Wang H; Jahreis A; Zitnik R; Chang T
J Am Acad Dermatol; 2006 Mar; 54(3 Suppl 2):S101-11. PubMed ID: 16488320
[TBL] [Abstract][Full Text] [Related]
22. Characteristics affecting health-related quality of life (HRQOL) in Japanese patients with reflux oesophagitis and the effect of lansoprazole on HRQOL.
Hongo M; Kinoshita Y; Miwa H; Ashida K
J Med Econ; 2009 Sep; 12(3):182-91. PubMed ID: 19691444
[TBL] [Abstract][Full Text] [Related]
23. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.
Menter A; Augustin M; Signorovitch J; Yu AP; Wu EQ; Gupta SR; Bao Y; Mulani P
J Am Acad Dermatol; 2010 May; 62(5):812-8. PubMed ID: 20219265
[TBL] [Abstract][Full Text] [Related]
24. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
Mease PJ; Revicki DA; Szechinski J; Greenwald M; Kivitz A; Barile-Fabris L; Kalsi J; Eames J; Leirisalo-Repo M
J Rheumatol; 2008 Jan; 35(1):20-30. PubMed ID: 18050385
[TBL] [Abstract][Full Text] [Related]
25. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.
Revicki D; Willian MK; Saurat JH; Papp KA; Ortonne JP; Sexton C; Camez A
Br J Dermatol; 2008 Mar; 158(3):549-57. PubMed ID: 18047521
[TBL] [Abstract][Full Text] [Related]
26. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis.
Revicki DA; Willian MK; Menter A; Gordon KB; Kimball AB; Leonardi CL; Langley RG; Kimel M; Okun M
J Dermatolog Treat; 2007; 18(6):341-50. PubMed ID: 18058494
[TBL] [Abstract][Full Text] [Related]
27. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial.
Langley RG; Feldman SR; Han C; Schenkel B; Szapary P; Hsu MC; Ortonne JP; Gordon KB; Kimball AB
J Am Acad Dermatol; 2010 Sep; 63(3):457-65. PubMed ID: 20462664
[TBL] [Abstract][Full Text] [Related]
28. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort.
Dalaker M; Bonesrønning JH
J Eur Acad Dermatol Venereol; 2009 Mar; 23(3):277-82. PubMed ID: 19207642
[TBL] [Abstract][Full Text] [Related]
29. Approach to managing patients with nail psoriasis.
Reich K
J Eur Acad Dermatol Venereol; 2009 Sep; 23 Suppl 1():15-21. PubMed ID: 19686381
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study.
Rigopoulos D; Gregoriou S; Stratigos A; Larios G; Korfitis C; Papaioannou D; Antoniou C; Ioannides D
Br J Dermatol; 2008 Aug; 159(2):453-6. PubMed ID: 18565184
[TBL] [Abstract][Full Text] [Related]
31. The effect of treatment on quality of life in psoriasis patients.
Prins M; Krabbe PF; Swinkels QO; de Boo T; van de Kerkhof PC; van der Valk PG
Acta Derm Venereol; 2005; 85(4):304-10. PubMed ID: 16191850
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
[TBL] [Abstract][Full Text] [Related]
33. Treatment of severe psoriasis with infliximab: report of two cases.
Peternel S; Prpić-Massari L; Guina T; Novak S; Brajac I; Kastelan M
Acta Dermatovenerol Croat; 2009; 17(3):204-6. PubMed ID: 19818221
[TBL] [Abstract][Full Text] [Related]
34. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year.
Rich P; Griffiths CE; Reich K; Nestle FO; Scher RK; Li S; Xu S; Hsu MC; Guzzo C
J Am Acad Dermatol; 2008 Feb; 58(2):224-31. PubMed ID: 18083272
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.
Kaltwasser JP; Nash P; Gladman D; Rosen CF; Behrens F; Jones P; Wollenhaupt J; Falk FG; Mease P;
Arthritis Rheum; 2004 Jun; 50(6):1939-50. PubMed ID: 15188371
[TBL] [Abstract][Full Text] [Related]
36. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens.
Gniadecki R; Robertson D; Molta CT; Freundlich B; Pedersen R; Li W; Boggs R; Zbrozek AS
J Eur Acad Dermatol Venereol; 2012 Nov; 26(11):1436-43. PubMed ID: 22035157
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment.
DE Oliveira JP; Levy A; Morel P; Guibal F
J Dermatol; 2008 Sep; 35(9):575-80. PubMed ID: 18837702
[TBL] [Abstract][Full Text] [Related]
38. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany.
Augustin M; Krüger K; Radtke MA; Schwippl I; Reich K
Dermatology; 2008; 216(4):366-72. PubMed ID: 18319601
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients].
Puig L
Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():30-5. PubMed ID: 19080989
[TBL] [Abstract][Full Text] [Related]
40. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab.
Cauza E; Spak M; Cauza K; Hanusch-Enserer U; Dunky A; Wagner E
Rheumatol Int; 2002 Nov; 22(6):227-32. PubMed ID: 12426660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]